

Henlius Biotech (2696 HK)

Accelerating global commercialization and innovation

Henlius delivered strong FY25 financial results, driven by robust product sales growth. The Company is expanding its global biosimilar footprint and forging new international partnerships. Henlius is accelerating its evolution into an innovative biologics powerhouse, spearheaded by competitive assets such as HLX43, HLX22, and serplulimab. Anticipating multiple clinical and regulatory catalysts in 2026, we maintain BUY rating on Henlius with a TP of HK\$99.78.

- FY25 product sales beat.** Henlius reported FY25 total revenue of RMB6.67bn (+16.5% YoY). Total product sales reached RMB5.77bn (+17.0% YoY), beating our previous full-year estimate of RMB5.35bn by ~7.9%, primarily driven by the continued ramp-up of serplulimab (PD-1, RMB1.50bn, +14.0% YoY). The foundational biosimilar franchise remained resilient, with trastuzumab generating global sales of RMB2.97bn (+5.5% YoY). Overseas product sales reached around RMB260mn in FY25, +100% YoY. Henlius maintained net profitability (RMB827mn) while stepping up its R&D investments to RMB2.49bn (+35.4% YoY) to fuel its next-generation pipeline.
- HLX43 (PD-L1 ADC) entering pivotal stages.** As a leading PD-L1 ADC globally, HLX43 has demonstrated competitive early efficacy signals in IO-resistant NSCLC. Among heavily pre-treated NSCLC patients, HLX43 delivered an ORR of 33.3% in sq-NSCLC (n=33) and an impressive 47.4% in EGFR wild-type nsq-NSCLC (n=19), with PFS data expected in 2026. A global Ph2 trial in late-line NSCLC is actively enrolling across the US, China, Japan, and Australia. Furthermore, Henlius has initiated a global Ph2/3 trial evaluating HLX43 +/- HLX07 (EGFR mAb) for IO-resistant sq-NSCLC (vs docetaxel), with the Ph2 portion expected to complete enrollment in 4Q26. We anticipate initiation of additional pivotal trials for HLX43 in NSCLC (including EGFR wild-type IO-resistant nsq-NSCLC and EGFRm NSCLC) by 4Q26.
- Executing serplulimab's global commercialization and label expansion.** The 1L ES-SCLC US bridging study completed enrollment in Oct 2025, targeting ESMO 2026 data readout and a 2026 US BLA submission. For perioperative GC, Ph3 data is expected at ASCO (Jun 2026) alongside a mid-2026 China NDA approval. In 1L MSS CRC, following demonstrated PFS and OS improvements in a Ph2 trial (serplulimab + chemo + bevacizumab), a Ph3 MRCT across China, Japan, and SEA fully enrolled in mid-2025, with data expected in 2027. The asset's value was further validated by an out-licensing deal with Eisai (4523 JP, NR) about Japan rights in Feb, securing a US\$75mn upfront payment.
- HLX22 (HER2 mAb) shows best-in-class efficacy in gastric cancer.** HLX22 is emerging as a formidable alternative for 1L HER2+ GC. In a Ph2 trial with a median follow-up of 28.5 months, the addition of HLX22 to the standard of care (trastuzumab + chemotherapy) dramatically improved efficacy. Median PFS was not reached in the HLX22 arm versus 8.3 months in the SoC arm, translating to an exceptional hazard ratio of 0.2. Henlius is advancing a global Ph3 MRCT in 1L HER2+ GC across China, the US, Japan, and Europe, with data readouts expected in 1H27.
- Maintain BUY.** Factoring in the strong product sales beat in 2025, we slightly revise our DCF-derived target price to HK\$99.78 from HK\$97.75 (WACC: 9.13%, terminal growth rate: 3.5%, both unchanged).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	5,724	6,667	7,336	6,665	7,522
YoY growth (%)	6.1	16.5	10.0	(9.1)	12.9
Net profit (RMB mn)	820.5	827.0	847.2	499.6	830.3
YoY growth (%)	50.3	0.8	2.4	(41.0)	66.2
EPS (Reported) (RMB)	1.51	1.52	1.56	0.92	1.53
P/E (x)	38.2	37.9	37.0	62.7	37.8

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$99.78
(Previous TP)	HK\$97.75)
Up/Downside	52.0%
Current Price	HK\$65.65

China Healthcare

Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288

andywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	35,680.4
Avg 3 mths t/o (HK\$ mn)	61.5
52w High/Low (HK\$)	88.70/25.60
Total Issued Shares (mn)	543.5

Source: FactSet

Shareholding Structure

Fosun	71.5%
Lin Lijun	3.1%


Source: Wind

Share Performance

	Absolute	Relative
1-mth	-5.4%	5.1%
3-mth	7.6%	13.8%
6-mth	-14.7%	-8.5%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (RMB mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	870	506	845	1,134	1,932	3,106	4,501	5,312	6,199	6,799
Less: Tax	(17)	(10)	(17)	(171)	(291)	(470)	(685)	(815)	(959)	(1,061)
Depreciation and amortisation		459	452	445	367	361	356	352	348	344
CAPEX (incl. intangible assets)		(1,123)	(1,023)	(973)	(973)	(973)	(973)	(973)	(973)	(973)
Change in working capital	750	(61)	(46)	(56)	(81)	(65)	(77)	(64)	(64)	(15)
FCF	940	(137)	253	301	949	1,954	3,118	3,807	4,548	5,090
Terminal value										93,517
PV of enterprise (RMB mn)	49,722									
Debt & Preferred Stock (RMB mn)	1,891									
Deposit and pledged cash (RMB mn)	543									
Equity value (RMB mn)	47,831									
Value per share (RMB)	88.01									
Value per share (HK\$)	99.78									
Terminal growth rate	3.5%									
WACC	9.13%									
Risk free rate	3.0%									
Market return	13.5%									
Premium	10.50%									
Beta	0.90									
Tax rate	15%									
Debt portion	35%									
Equity portion	65%									
Cost of equity	12.5%									
Cost of debt	3.5%									
Cost of debt (tax shielded)	3.0%									

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

		WACC				
		8.13%	8.63%	9.13%	9.63%	10.13%
Terminal growth rate	4.5%	159.66	136.42	118.30	103.80	91.95
	4.0%	142.18	123.27	108.14	95.78	85.51
	3.5%	128.46	112.68	99.78	89.06	80.04
	3.0%	117.42	103.96	92.78	83.36	75.33
	2.5%	108.34	96.67	86.84	78.46	71.24

Source: CMBIGM estimates

Figure 3: CMBIGM estimates: new vs old

RMB mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	7,336	6,665	7,522	4,855	5,610	6,525	51%	19%	15%
Gross profit	5,404	4,593	5,344	3,478	4,135	4,952	55%	11%	8%
Net profit	847	500	830	469	809	1,200	81%	-38%	-31%
EPS (RMB)	1.56	0.92	1.53	0.86	1.49	2.21	81%	-38%	-31%
Gross margin	73.67%	68.91%	71.05%	71.65%	73.70%	75.90%	+2.02 ppt	-4.79 ppt	-4.86 ppt
Net margin	11.55%	7.50%	11.04%	9.66%	14.42%	18.39%	+1.89 ppt	-6.93 ppt	-7.35 ppt

Source: CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	7,336	6,665	7,522	6,441	7,107	8,983	14%	-6%	-16%
Gross profit	5,404	4,593	5,344	4,622	5,059	6,963	17%	-9%	-23%
Net profit	847	500	830	1,032	1,116	1,628	-18%	-55%	-49%
EPS (RMB)	1.56	0.92	1.53	1.55	2.06	2.73	1%	-55%	-44%
Gross margin	73.67%	68.91%	71.05%	71.76%	71.19%	77.51%	+1.91 ppt	-2.28 ppt	-6.46 ppt
Net margin	11.55%	7.50%	11.04%	16.01%	15.70%	18.13%	-4.46 ppt	-8.20 ppt	-7.09 ppt

Source: Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	5,395	5,724	6,667	7,336	6,665	7,522
Cost of goods sold	(1,476)	(1,540)	(1,682)	(1,932)	(2,072)	(2,178)
Gross profit	3,919	4,185	4,985	5,404	4,593	5,344
Selling expense	(1,754)	(1,917)	(2,198)	(2,447)	(1,899)	(2,079)
Admin expense	(384)	(371)	(443)	(496)	(437)	(495)
R&D expense	(1,119)	(1,035)	(1,515)	(1,591)	(1,750)	(1,925)
Operating profit	662	861	828	870	506	845
Other gains/(losses)	(92)	(15)	(16)	(6)	4	3
EBITDA	1,015	1,228	1,295	1,330	958	1,290
EBIT	662	861	828	870	506	845
Pre-tax profit	570	846	812	865	510	847
Income tax	(24)	(25)	15	(17)	(10)	(17)
After tax profit	546	820	827	847	500	830
Minority interest	0	0	0	0	0	0
Net profit	546	820	827	847	500	830

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Current assets	2,676	2,512	3,486	3,585	3,539	3,601
Cash & equivalents	988	773	772	1,706	1,573	1,580
Restricted cash	0	0	0	0	0	0
Account receivables	648	857	1,816	746	772	782
Inventories	757	728	612	847	908	955
Other current assets	283	153	286	286	286	286
Non-current assets	7,228	8,086	8,875	9,539	10,110	10,638
PP&E	2,238	2,343	2,262	2,186	2,117	2,055
Right-of-use assets	415	357	320	248	176	104
Intangibles	4,511	5,355	6,162	6,974	7,686	8,348
Other non-current assets	64	30	131	131	131	131
Total assets	9,904	10,598	12,361	13,124	13,649	14,240
Current liabilities	5,067	5,032	4,941	4,856	4,882	4,891
Short-term borrowings	2,800	2,560	2,247	2,247	2,247	2,247
Account payables	545	729	831	746	772	782
Other current liabilities	1,255	1,299	1,345	1,345	1,345	1,345
Contract liabilities	467	444	518	518	518	518
Non-current liabilities	2,644	2,552	3,460	3,460	3,460	3,460
Long-term borrowings	1,293	1,089	1,350	1,350	1,350	1,350
Deferred income	230	239	277	277	277	277
Other non-current liabilities	1,121	1,225	1,832	1,832	1,832	1,832
Total liabilities	7,711	7,584	8,401	8,316	8,342	8,351
Share capital	543	543	543	543	543	543
Retained earnings	1,649	2,470	3,417	4,264	4,764	5,345
Total shareholders equity	2,192	3,014	3,960	4,808	5,307	5,888
Total liabilities and shareholders equity	9,904	10,598	12,361	13,124	13,649	14,240

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	570	846	812	865	510	847
Depreciation & amortization	353	367	468	459	452	445
Tax paid	(21)	(28)	15	(17)	(10)	(17)
Change in working capital	61	(57)	(212)	750	(61)	(46)
Others	85	114	102	102	102	102
Net cash from operations	1,048	1,242	1,185	2,159	992	1,331
Investing						
Capital expenditure	(474)	(164)	(150)	(150)	(150)	(150)
Others	(531)	(746)	(974)	(973)	(873)	(823)
Net cash from investing	(1,004)	(910)	(1,124)	(1,123)	(1,023)	(973)
Financing						
Dividend paid	0	0	0	0	0	(249)
Net borrowings	365	(408)	0	0	0	0
Proceeds from share issues	0	0	0	0	0	0
Others	(220)	(236)	(102)	(102)	(102)	(102)
Net cash from financing	144	(643)	(102)	(102)	(102)	(351)
Net change in cash						
Cash at the beginning of the year	673	868	773	772	1,706	1,573
Exchange difference	6	15	0	0	0	0
Cash at the end of the year	868	571	731	1,706	1,573	1,580
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	67.8%	6.1%	16.5%	10.0%	(9.1%)	12.9%
Gross profit	65.3%	6.8%	19.1%	8.4%	(15.0%)	16.4%
Operating profit	na	30.1%	(3.9%)	5.1%	(41.9%)	67.0%
EBITDA	na	21.0%	5.5%	2.7%	(28.0%)	34.7%
EBIT	na	30.1%	(3.9%)	5.1%	(41.9%)	67.0%
Net profit	na	50.3%	0.8%	2.4%	(41.0%)	66.2%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	72.6%	73.1%	74.8%	73.7%	68.9%	71.0%
Operating margin	12.3%	15.0%	12.4%	11.9%	7.6%	11.2%
EBITDA margin	18.8%	21.5%	19.4%	18.1%	14.4%	17.1%
Return on equity (ROE)	28.5%	31.5%	23.7%	19.3%	9.9%	14.8%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Current ratio (x)	0.5	0.5	0.7	0.7	0.7	0.7
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	57.4	38.2	37.9	37.0	62.7	37.8
P/B	14.3	10.4	7.9	6.5	5.9	5.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.